[Unaltered homocysteine levels during simvastatin therapy]

Area of Science:

• Cardiovascular Medicine
• Clinical Pharmacology

Background:

• Elevated homocysteine levels are a known risk factor for vascular disease.
• Certain medications, including some lipid-lowering drugs, can increase plasma homocysteine.
• Familial heterozygous hypercholesterolemia is a condition requiring lipid-lowering treatment.

Purpose of the Study:

• To investigate the effect of simvastatin on plasma homocysteine levels.
• To determine if simvastatin influences homocysteine concentrations in patients with severe hypercholesterolemia.

Main Methods:

• A study involving 57 patients with severe familial heterozygous hypercholesterolemia.
• Plasma homocysteine levels were measured before and after 1, 3, and 6 months of simvastatin therapy.
• Analysis included comparisons based on sex, smoking status, and simvastatin dosage (20 mg vs. 40 mg).

Main Results:

• Simvastatin therapy did not result in any significant change in plasma homocysteine levels.
• Males exhibited higher homocysteine levels than females.
• Smokers generally had higher homocysteine concentrations than non-smokers.
• No difference was observed between patients receiving 20 mg or 40 mg of simvastatin.
• No correlation was found between simvastatin's lipid-lowering effect and homocysteine levels.

Conclusions:

• Simvastatin does not appear to affect plasma homocysteine levels.
• This finding contrasts with other lipid-lowering agents that have been shown to increase homocysteine.
• Simvastatin can be used in patients with hypercholesterolemia without concern for elevated homocysteine levels.